<DOC>
	<DOCNO>NCT01565616</DOCNO>
	<brief_summary>The primary goal multicenter study determine safety feasibility Bone Marrow Transplantation ( BMT ) young adult severe sickle cell disease ( SCD ) use reduce toxicity condition regimen consist busulfan ( Bu ) / fludarabine ( Flu ) / anti-thymocyte globulin ( ATG ) . A two-component design use study . The first component restrict patient HLA-identical sibling donor . Five patient enrol first component study . The second component enrollment include patient related unrelated HLA-matched donor . Up 10 additional patient enrol component study .</brief_summary>
	<brief_title>Bone Marrow Transplantation Young Adults With Severe Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Diagnosis severe sickle cell disease denote one following : Clinically significant neurologic event neurological deficit last great 24 hour 2 episode acute chest syndrome last 2 year despite use supportive care measure 3 severe vasoocclusive pain episode per year last 2 year despite supportive care measure Receives regular RBC transfusion therapy , define 8 transfusion per year 1 year longer Echocardiograph find Tricuspid Regurgitation Jet ( TRJ ) velocity 2.7 m/sec great Adequate physical function Must 8 8 HLAA , B , C , DRB1 allele match related unrelated bone marrow donor Patients cirrhosis liver , uncontrolled bacterial , viral fungal infection past month , seropositivity HIV Patients receive prior HCT Females pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Severe Sickle Cell Disease</keyword>
	<keyword>HCT</keyword>
	<keyword>Hematopoietic Stem Cell Therapy</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Genetic Diseases</keyword>
	<keyword>Anemia</keyword>
	<keyword>Hemolytic</keyword>
	<keyword>Congenital</keyword>
	<keyword>Human Leukocyte Antigen</keyword>
	<keyword>HLA</keyword>
</DOC>